Hormone and Cytokine Circadian Alteration in Non-small Cell Lung Cancer Patients
Overview
Pathology
Pharmacology
Authors
Affiliations
Alterations in hormone secretion and cytokine levels have been evidenced in many neoplastic diseases. In this study we have evaluated the circadian profile of growth hormone (GH), insulin-like growth factor-1 (IGF-1), interleukin-2 (IL2), melatonin (MEL) and cortisol (COR) serum levels in non-small cell lung cancer patients. Blood was sampled every 4 h for 24 h in 11 healthy (H) men (ages 35-53 years) and 9 men with stage 2, 3 or 4 non-small cell lung cancer (C) (ages 43-63 years). Serum GH, total IGF1, IL2, MEL and COR were measured and examined for group differences, trends, and rhythm characteristics. 24-h means were significantly higher in C234 vs H for GH, GH/IGF1, IL2 and COR, and lower for IGF1, but IL2 and COR were not different for C23 vs H. A linear regression across 4 groups (H, C2, C3, C4) found a positive trend for COR, GH, GH/IGF1 and IL2, and a negative trend for IGF1. A linear regression run between the 24-h mean levels of GH, IGF1, COR, MEL and IL2 in healthy subjects evidenced a statistically significant positive trend between MEL and GH (R = 0.281, p = 0.022) and in cancer patients showed a statistically significant negative trend between GH and IGF1 (R = 0.332, p = 0.01), COR and IGF1 (R=0.430, p=0.001), and a statistically significant positive trend between the 24-h mean of COR and GH (R = 0.304, p = 0.02). Rhythms in MEL and COR (peaks near 01:00h and 08:00h, respectively) indicated identical synchronization to the light-dark cycle for both groups. A circadian rhythm was detected in GH and GH/IGF1 for C23 and H, with IGF1 and IL2 non-rhythmic in any group. In conclusion, an increasing trend and progressive loss of circadian rhythmicity in GH and GH/IGF1, an increasing trend in cortisol and IL2, and a decreasing trend in IGF1 in C, reflect a complex chain of events that could be involved in progression of neoplastic disease. A therapeutic strategy needs to take into account circadian patterns and complex interactions of the multiple functions that characterize the hormone and cytokine levels in the frame cancer progression.
Review: therapeutic approaches for circadian modulation of the glioma microenvironment.
Nettnin E, Nguyen T, Arana S, Barros Guinle M, Garcia C, Gibson E Front Oncol. 2024; 13:1295030.
PMID: 38173841 PMC: 10762863. DOI: 10.3389/fonc.2023.1295030.
Circadian rhythm disorders in patients with advanced cancer: a scoping review.
Gouldthorpe C, Power J, Davies A Front Oncol. 2023; 13:1240284.
PMID: 37829342 PMC: 10565850. DOI: 10.3389/fonc.2023.1240284.
Fenofibrate prevents skeletal muscle loss in mice with lung cancer.
Goncalves M, Hwang S, Pauli C, Murphy C, Cheng Z, Hopkins B Proc Natl Acad Sci U S A. 2018; 115(4):E743-E752.
PMID: 29311302 PMC: 5789923. DOI: 10.1073/pnas.1714703115.
Immunotherapy for lung cancer: advances and prospects.
Yang L, Wang L, Zhang Y Am J Clin Exp Immunol. 2016; 5(1):1-20.
PMID: 27168951 PMC: 4858602.
Crosstalk between the circadian clock circuitry and the immune system.
Cermakian N, Lange T, Golombek D, Sarkar D, Nakao A, Shibata S Chronobiol Int. 2013; 30(7):870-88.
PMID: 23697902 PMC: 7195843. DOI: 10.3109/07420528.2013.782315.